JMDC Inc.

DB:6JM Stock Report

Market Cap: €1.5b

JMDC Valuation

Is 6JM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6JM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6JM (€22.6) is trading above our estimate of fair value (€12.07)

Significantly Below Fair Value: 6JM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6JM?

Key metric: As 6JM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6JM. This is calculated by dividing 6JM's market cap by their current earnings.
What is 6JM's PE Ratio?
PE Ratio61x
EarningsJP¥4.13b
Market CapJP¥252.15b

Price to Earnings Ratio vs Peers

How does 6JM's PE Ratio compare to its peers?

The above table shows the PE ratio for 6JM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.3x
NXU Nexus
45.1x17.1%€1.2b
COP CompuGroup Medical SE KGaA
44.7x30.5%€1.1b
M3V MeVis Medical Solutions
7.7xn/a€44.4m
AJ91 DocCheck
15.9xn/a€38.8m
6JM JMDC
61x25.0%€252.1b

Price-To-Earnings vs Peers: 6JM is expensive based on its Price-To-Earnings Ratio (61x) compared to the peer average (28.3x).

Price to Earnings Ratio vs Industry

How does 6JM's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
6JM 61.0xIndustry Avg. 32.6xNo. of Companies5PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6JM is expensive based on its Price-To-Earnings Ratio (61x) compared to the Global Healthcare Services industry average (32.6x).

Price to Earnings Ratio vs Fair Ratio

What is 6JM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6JM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61x
Fair PE Ratio28.9x

Price-To-Earnings vs Fair Ratio: 6JM is expensive based on its Price-To-Earnings Ratio (61x) compared to the estimated Fair Price-To-Earnings Ratio (28.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6JM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€22.60
€34.72
+53.6%
15.7%€43.41€24.18n/a11
Dec ’25€24.60
€34.79
+41.4%
17.2%€43.41€24.19n/a11
Nov ’25€24.20
€34.63
+43.1%
18.9%€44.28€24.67n/a11
Oct ’25€28.60
€34.63
+21.1%
18.9%€44.28€24.67n/a11
Sep ’25€26.00
€32.41
+24.7%
22.1%€43.32€22.28n/a11
Aug ’25€18.80
€28.27
+50.4%
27.9%€40.86€19.44n/a10
Jul ’25€17.40
€28.24
+62.3%
30.4%€41.02€19.51n/a9
Jun ’25€15.70
€28.93
+84.3%
29.0%€41.01€19.51n/a10
May ’25€18.70
€32.81
+75.5%
22.0%€42.53€22.18n/a10
Apr ’25€21.80
€36.19
+66.0%
25.0%€56.39€22.62n/a10
Mar ’25€23.00
€36.76
+59.8%
25.0%€56.56€22.69n/a10
Feb ’25€23.60
€39.10
+65.7%
24.8%€63.39€28.35n/a10
Jan ’25€26.60
€40.41
+51.9%
23.6%€64.87€30.12n/a10
Dec ’24€25.80
€39.27
+52.2%
23.3%€61.77€28.68€24.6010
Nov ’24€26.60
€41.60
+56.4%
24.7%€66.35€30.39€24.2010
Oct ’24€33.60
€43.10
+28.3%
25.1%€66.38€30.41€28.608
Sep ’24€27.00
€42.41
+57.1%
26.7%€66.14€30.30€26.009
Aug ’24€33.60
€45.32
+34.9%
21.1%€66.29€33.78€18.809
Jul ’24n/a
€44.67
0%
22.3%€66.06€33.66€17.409
Jun ’24€36.60
€45.35
+23.9%
22.0%€64.03€34.01€15.709
May ’24€31.60
€47.07
+48.9%
24.5%€66.00€32.65€18.708
Apr ’24€30.40
€47.31
+55.6%
26.3%€66.65€32.98€21.807
Mar ’24€28.40
€47.50
+67.2%
26.8%€67.23€33.26€23.007
Feb ’24€29.60
€47.78
+61.4%
26.8%€67.17€30.40€23.607
Jan ’24€26.20
€50.48
+92.7%
25.5%€70.88€35.09€26.607
Dec ’23€35.60
€52.40
+47.2%
23.5%€68.05€36.75€25.806

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 17:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JMDC Inc. is covered by 16 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ritsuo WatanabeBofA Global Research
Tomoko YoshiharaDaiwa Securities Co. Ltd.
Ei KyokuDaiwa Securities Co. Ltd.